A diverse and broad development pipeline

Late-stage

Early-stage



The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

* Enfortumab vedotin — Approved in the U.S. to treat certain types of metastatic urothelial cancer post PD(L)-1 inhibitor and a platinum-containing chemotherapy.
§ Tucatinib is approved for use in several countries. Registration requirements as well as prescribing information may vary per country of registration of tucatinib.

† Program being co-developed with Astellas Pharma Inc.; EV-304, EV-303, EV-302 and EV-103 with Astellas and Merck; ‡ Program being co-developed with Genmab A/S; ¶ Program being co-developed with Merck;
# Conducted in collaboration with Alliance for Clinical Trials in Oncology and National Cancer Institute (NCI)

HER2: human epidermal growth factor receptor-2; **PD-1:** programmed cell death 1; **PD-L1:** programmed death ligand 1; **SEA:** sugar-engineered antibody; **T-DM1:** ado-trastuzumab emtansine.

References:
1. https://clinicaltrials.gov/ct2/show/NCT04700124
2. https://clinicaltrials.gov/ct2/show/NCT03924895
3. https://clinicaltrials.gov/ct2/show/NCT04223856
4. https://clinicaltrials.gov/ct2/show/NCT03474107
5. https://clinicaltrials.gov/ct2/show/NCT04225117
6. https://clinicaltrials.gov/ct2/show/NCT03219333
7. https://clinicaltrials.gov/ct2/show/NCT02091999
8. https://clinicaltrials.gov/ct2/show/NCT03975647
9. https://clinicaltrials.gov/ct2/show/NCT04457596
10. https://clinicaltrials.gov/ct2/show/NCT04539938
11. https://clinicaltrials.gov/ct2/show/NCT04579380
12. https://clinicaltrials.gov/ct2/show/NCT03043313
13. https://clinicaltrials.gov/ct2/show/NCT04499924
14. https://clinicaltrials.gov/ct2/show/NCT04430738
15. https://clinicaltrials.gov/ct2/show/NCT04697628
16. https://clinicaltrials.gov/ct2/show/NCT03438396
17. https://clinicaltrials.gov/ct2/show/NCT03786081
18. https://clinicaltrials.gov/ct2/show/NCT03913741
19. https://clinicaltrials.gov/ct2/show/NCT03485209
20. https://clinicaltrials.gov/ct2/show/NCT03657043
21. https://clinicaltrials.gov/ct2/show/NCT04032704
22. https://clinicaltrials.gov/ct2/show/NCT03310957
23. https://clinicaltrials.gov/ct2/show/NCT01969643
24. https://clinicaltrials.gov/ct2/show/NCT03582033
25. https://clinicaltrials.gov/ct2/show/NCT02376699
26. https://clinicaltrials.gov/ct2/show/NCT04042480
27. https://clinicaltrials.gov/ct2/show/NCT04227847
28. https://clinicaltrials.gov/ct2/show/NCT04254107
29. https://clinicaltrials.gov/ct2/show/NCT04389632

Accessed: February 16 2021